Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 194, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112260
Keywords
Matrix metalloproteinase; MMP-9; MMP-9 inhibitor; Cancer; Hydroxamate
Categories
Funding
- All India Council for Technical Education (AICTE) New Delhi
- Council of Scientific and Industrial Research, India (CSIR), New Delhi, India [09/096(0966)/2019-EMR-I]
- RUSA 2.0 of University Grant Commission (UGC), New Delhi, India [R-11/1030/19]
- CSIR, New Delhi, India [09/096(0967)/2019-EMR-I]
- RUSA 2.0 of UGC New Delhi
Ask authors/readers for more resources
Matrix metalloproteinases (MMPs) are zinc dependent proteolytic metalloenzyme. MMP-9 is one of the most complex forms of matrix metalloproteinases. MMP-9 has the ability to degrade the extracellular matrix (ECM) components and has important role in the pathophysiological functions. Overexpression and dysregulation of MMP-9 is associated with various diseases. Thus, regulation and inhibition of MMP9 is an important therapeutic approach for combating various diseases including cancer. Inhibitors of MMP-9 can be used as anticancer agents. Till date no selective MMP-9 inhibitors passed the clinical trials. In this review the structure, activation, function and inhibitors of MMP-9 are mainly focused. Some highly active and/or selective MMP-9 inhibitors have been discussed which may be helpful to explore the structural significance of MMP-9 inhibitors. This study may be useful to design new potent and selective MMP-9 inhibitors against cancer in future. (C) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available